Results 21 to 30 of about 55,457 (267)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

open access: yesClinicoEconomics and Outcomes Research, 2015
George Dranitsaris,1 Bo Yu,2 Jennifer King,3 Satyin Kaura,3 Adams Zhang3 1Augmentium Pharma Consulting Inc., Toronto, ON, Canada; 2Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; 3Celgene Corporation, Summit, NJ, USA ...
Dranitsaris G   +4 more
doaj   +1 more source

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting

open access: yesLung Cancer: Targets and Therapy, 2017
Raja Mudad,1 Manish B Patel,2 Sandra Margunato-Debay,2 David Garofalo,3 Lincy S Lal4 1University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Hollywood, FL, USA; 2Celgene Corporation, Summit, NJ, USA; 3Cardinal Health ...
Mudad R   +4 more
doaj   +2 more sources

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial

open access: yesDrug Design, Development and Therapy, 2018
Cesare Gridelli,1 Tianlei Chen,2 Amy Ko,2 Mary E O’Brien,3 Teng Jin Ong,4 Mark A Socinski,5 Pieter E Postmus6 1Division of Medical Oncology, S. G.
Gridelli C   +6 more
doaj   +1 more source

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety

open access: yesBMC Cancer, 2022
Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with a poor prognosis. Approximately 20% of TNBC has been found to express programmed death ligand 1 (PD-L1), making it a potential therapeutic target.
K. Sharmni Vishnu   +3 more
doaj   +1 more source

Macular Cystoid Edema Induced by Nab-Paclitaxel

open access: yesActa Médica Portuguesa, 2022
A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively.
Sara Alves Pereira   +3 more
openaire   +4 more sources

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer

open access: yesBMC Cancer, 2021
Background Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be ...
Haili Lu   +8 more
doaj   +1 more source

Supplementary Material for: Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel

open access: yes, 2023
We present a rare phenomenon of a soft tumor hanging on the woman’s left upper arm that underwent necrosis from the distal aspect during chemotherapy for pancreatic cancer.
Yongshun Huang (746405)   +3 more
core   +1 more source

Comparison of Peripheral Neuropathy Induced by Standard and Nanoparticle Albumin–Bound Paclitaxel in Rats

open access: yesJournal of Pharmacological Sciences, 2011
.: Nanoparticle albumin–bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel.
Yuji Yamashita   +5 more
doaj   +1 more source

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2023
Stress cardiomyopathy is a transient left ventricular dysfunction caused by physiologic or pathologic stressors. Anaphylaxis is a hypersensitivity disorder that can lead to a rapid life-threatening respiratory collapse. It happens due to exposure to allergens including medications.
Harjinder Singh   +3 more
openaire   +3 more sources

Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis

open access: yesArtificial Cells, Nanomedicine, and Biotechnology, 2019
Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) offer more efficient paclitaxel delivery into tumor cells with fewer side effects than conventional chemotherapies.
Hong Tan, Jing Hu, Shan Liu
doaj   +1 more source

Home - About - Disclaimer - Privacy